NFKB1 and Miyoshi myopathy: Aberrant activation of the NF-κB pathway has been observed in MM [167], while CYLD is a negative regulator of NF-κB pathway, and the status of CYLD at 16q12 is highly correlated with the clinical outcome of MM patients [168].